ORGO Stock News & Catalysts – Organogenesis

FEATURED

Organogenesis Holdings Inc. Reports Third Quarter 2026 Financial Results

CANTON, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development,

Summary

Nov 5, 2026, 4:05 PM ·Globe Newswire

RECENT

Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabetic Foot Ulcers

CANTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports

Oct 12, 2026, 4:10 PM ·Globe Newswire

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026

CANTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development,

Oct 12, 2026, 4:05 PM ·Globe Newswire

Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results

CANTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development,

Aug 6, 2026, 4:05 PM ·Globe Newswire

Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers

CANTON, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports

Jul 27, 2026, 4:05 PM ·Globe Newswire

One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics

Issued on behalf of Conexeu Sciences Inc.Conexeu Sciences Inc. (NASDAQ:CNXU) completed the 12-month P.R.O.O.F phase of its CXU preclinical program, which met its objectives across three pillars, facial, body, and

Jul 9, 2026, 8:16 AM ·PRNewswire

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026

CANTON, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development,

Jul 9, 2026, 7:30 AM ·Globe Newswire

Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis

CANTON, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports

Jul 6, 2026, 4:05 PM ·Globe Newswire

Regenerative Medicine's Next Chapter: Inside the Race to Make the Body Rebuild Itself

Issued on behalf of Conexeu Sciences Inc. A sector analysis of regenerative medicine — the science of restoring tissue rather than merely replacing it — and where a new generation of platform companies is trying to fit

Jun 18, 2026, 12:42 PM ·Globe Newswire

The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It

Issued on behalf of Conexeu Sciences Inc. A new generation of tissue companies is betting that the future of wound care and reconstruction isn't a better patch — it's a material that helps the body regrow

Jun 16, 2026, 10:30 AM ·Globe Newswire

The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts

Issued on behalf of Conexeu Sciences Inc.A newly listed regenerative-tissue company has put its lead breast-reconstruction matrix on the bench at one of the world's largest bioprinting institutes. For investors

Jun 2, 2026, 9:00 AM ·PRNewswire

Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results

CANTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development,

May 7, 2026, 4:05 PM ·Globe Newswire

Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®

CANTON, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions

Apr 28, 2026, 4:30 PM ·Globe Newswire

Organogenesis Holdings, Inc. Investigated by the Portnoy Law Firm

LOS ANGELES, April 15, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Organogenesis Holdings, Inc. ("Organogenesis" or the "Company") (NASDAQ:ORGO) investors that the firm has initiated an

Apr 15, 2026, 9:00 AM ·Globe Newswire

Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM

Statistically significant (p<0.0477) DFU wound closure at 12 weeksRCT compared PuraPly®AM plus standard of care to standard of care aloneResults strengthen existing clinical evidence supporting future coverage

Apr 6, 2026, 7:02 PM ·Globe Newswire

Organogenesis Holdings Inc. ORGO · News